Proteins related to lipoprotein profile were identified using a pharmaco-proteomic approach as markers for growth response to growth hormone (GH) treatment in short prepubertal children

Table 2 The most predictive peaks for delta height_SDS 0-2 year identified by regression analysis

Group	Patients (n=)	Peaks (n=)	R ²	Cross-validated R ²	p-value	Peak m/z value (kDa)
GHD	39	7	0,73	0,61	0,032	3.160, 3.318, 8.767 (Apo A-II), 9.135, 9.642, 12.872 (TTR), 17.390 (Apo A-II)
GHD	39	4	0,64	0,53	0,017	4.408 (Apo A-II), 8.696 (Apo A-II), 9.019 (Apo A-II), 17.146 (Apo A-II)
ISS	89	8	0,47	0,35	0,015	3.160, 4.470, 6.857 (Apo C-I), 8.767 (Apo A-II), 8.875 (Apo A-II), 9.425 (Apo C-III), 12.607 (SAA4), 12.872 (TTR)
Total	128	8	0,38	0,28	0,003	4.628, 4.470, 4.793, 8.817, 8.875, 9.019, 12.872, 17.146
GHD	39	4	0,59	0,48	0,026	4.138, 8.817 (Apo A-II), 9.019 (Apo A-II), 17.262 (Apo A-II)
Total	128	8	0,35	0,24	0,003	4.138, 8.636 (Apo A-II), 8.875 (Apo A-II), 9.135, 9.425 (Apo C-III), 14.055 (TTR), 28.090 (Apo A-I), 29.003

GHD, GH-deficient; ISS, idiopathic short stature.
The most predictive peaks identified by regression analysis at start, after 1 year, and during the first year of GH treatment. For each model, the R²-value and cross-validated R² are presented.

ISSN: 1477-5956